Comparison of the Effects of AcSDKP, Thymosin β4, Macrophage Inflammatory Protein 1α and Transforming Growth Factor β on Human Leukemic Cells

References

• Guigon M., Lemoine F. M., Dainiak N., Schechter A., Najman A. The negative regulation of hematopoiesis: from fundamental aspects to clinical applications. Colloque INSERM. John Libbey Eurotext. 1993; 229
   Google Scholar
• Sing G. K., Keller J. R., Ellingsworth L. R., Ruscetti F. W. Transforming growth factor β selectively inhibits normal and leukemic human bone marrow cell growth in vitro. Blood 1988; 72: 1504–1511
   PubMed Web of Science ®Google Scholar
• Graham G. H., Wright E. C., Hewick R., Wolpe S. D., Wilkie N. M., Donaldson D., Lorimore S., Pragnell I. B. Identification and characterization of an inhibitor of hematopoietic stem cell proliferation. Nature 1990; 44: 442–444
   Web of Science ®Google Scholar
• Broxmeyer H. E., Benninger L., Hague N., Hendrie P., Cooper S., Mantel C., Cornetta K., Vadhan‐Raj S., Sarris A., Lu L. Suppressive effects of the chemokine (macrophage inflammatory protein) family of cytokines on proliferation of normal and myeloid cells. The negative regulation of hematopoiesis: from fundamental aspects to clinical applications, M. Guigon, F. M. Lemoine, N. Dainiak, A. Schechter, A. Najman. John Libbey Eurotext, Paris‐London 1993; A. 229: 141–154
   Google Scholar
• Guigon M., Bonnet D., Lemoine F. M., Kobari L., Parmentier C., Mary J. Y., Najman A. Inhibition of human bone marrow progenitors by the synthetic tetrapep‐tide AcSDKP. Exp Hematol. 1990; 18: 1112–1115
   PubMed Web of Science ®Google Scholar
• Bonnet D., Lemoine F. M., Pontvert‐Delucq S., Baillou C., Najman A., Guigon M. Direct and reversible inhibitory effect of the tetrapeptide Acetyl‐N‐Ser‐Asp‐Lys‐Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors. Blood 1993; 82: 3307–3314
   PubMed Web of Science ®Google Scholar
• Bonnet D., Lemoine F. M., Frobert Y., Najman A., Guigon M. Thymosin β4, a novel inhibitor for normal hematopoietic progenitor cells. Exp. Hematol. 1996; 24: 776–782
   PubMed Web of Science ®Google Scholar
• Guigon M., Mary J. Y., Enouf J., Frindel E. Protection of mice against lethal doses of l‐fiarabinofura‐nosyl‐cytosine by pluripotent stem cell inhibitors. Cancer Res. 1982; 42: 638–642
   PubMed Web of Science ®Google Scholar
• Lord B. I., Dexter T. M., Clements J. M., Hunter M. A., Gearing A. J. H. Macrophage inflammatory protein protects multipotent hematopoietic cells from the cytotoxic effects of hydroxyurea in vivo. Blood 1992; 79: 2605–2609
   PubMed Web of Science ®Google Scholar
• Moscinski L., Naylor P. H., Oliver J., Goldstein A. L. Thymosin β4 synergizes with GM‐CSF in maintaining bone marrow proliferation. Immunopharmacology 1993; 26: 83–92
   PubMed Web of Science ®Google Scholar
• Grzegorzewski K., Ruscetti F. W., Usui N., Damia G., Longo D. L., Carlino J. A., Keller J. A., Wiltrout R. H. Recombinant transforming growth factor (31 and 02 protect mice from acutely lethal doses of 5‐Fluorouracil and Doxorubicin. J. Exp. Med 1994; 180: 1047–1057
   PubMed Web of Science ®Google Scholar
• Eaves C. J., Cashman J. D., Wolpe S. D., Eaves A. C. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein‐1α (MIP‐1α), an inhibitor of primitive normal hematopoietic cells. Proc. Natl. Acad. Sci. USA 1993; 90: 12015–12019
   PubMed Web of Science ®Google Scholar
• Ferrajoli A., Talpaz M., Zipf T. F., Hirsch‐Ginsberg C., Estey E., Wolpe S. D., Estrov Z. Inhibition of acute myelogenous leukemia progenitor proliferation by Macrophage Inflammatory Protein 1‐α. Leukemia 1994; 8: 798–805
   PubMed Web of Science ®Google Scholar
• Bonnet D., Césaire R., Lemoine F. M., Aoudjhane M., Najman A., Guigon M. The tetrapeptide AcSDKP, an inhibitor of the cell cycle status for normal human bone marrow progenitors, has no effect on leukemic cells. Exp Hematol 1992; 20: 251–255
   PubMed Web of Science ®Google Scholar
• Cashman J. D., Eaves A. C., Eaves C. J. The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long‐term culture: evidence for an indirect mechanism. Blood 1994; 84: 1534–1542
   PubMed Web of Science ®Google Scholar
• Bonnet D., Lemoine F. M., Liu L., Pontvert‐Delucq S., Baillou C., Najman A., Guigon M. Effects of the tetrapeptide AcSDKP (Seraspenide) on normal and malignant hematopoietic cells. The negative regulation of hematopoiesis: from fundamental aspects to clinical applications, M. Guigon, F. M. Lemoine, N. Dainiak, A. Schechter, A. Najman. John Libbey Eurotext, Paris‐London 1993; A. 229: 169–176
   Google Scholar
• Bonnet D., Lemoine F. M., Najman A., Guigon M. Comparison of the inhibitory effect of AcSDKP, TNFα, TGFβ and MIP1α on marrow‐purified CD34+ progenitors. Exp. Hematol. 1995; 13: 551–556
   Google Scholar
• Mantel C., Kim Y. J., Cooper S., Kwon B., Broxmeyer H. E. Polymerization of murine macrophage inflammatory protein‐1α inactives its myelosuppressive effects in vitro. The active form is monomer. Proc. Natl. Acad. Sci. USA 1993; 90: 2232–2236
   PubMed Web of Science ®Google Scholar
• Eder M., Ottmann O. G., Hansen‐Hagge T. E., Bartram C. R., Falk S., Gillis S., Hoelzer D., Ganser A. In vitro culture of common acute lymphoblastic leukemia cells. Effects of interleukin‐3, interleukin‐7 and accessory cells. Blood 1992; 79: 3274–3284
   PubMed Web of Science ®Google Scholar
• Pontvert‐Delucq S., Hibner U., Vilmer E., Baillou C., Rohrlich P., Heymann D., Guigon M., Najman A., Lemoine F. M. Heterogeneity of B lineage acute lymphoblastic leukemia (B‐ALL) with regard to their in vitro spontaneous proliferation, growth factor response and bcl‐2 expression. Leukemia and Lymphoma 1996; 21: 267–280
   PubMed Web of Science ®Google Scholar
• Mulletin J., Buffat L., Bonnet D., Guigon M., Mary J. Y. Revisiting methods to assess the effect of hematopoietic inhibitors using colony forming assays. Ann. NY. Acad. Sci. 1991; 628: 420–432
   PubMed Web of Science ®Google Scholar
• Delwel L., Salem M., Dorssers L., Wagemaker G., Clark S., Lowenberg B. Growth regulation of human acute myeloid leukemia: effect of five recombinant hematopoietic factors in a serum‐free culture system. Blood 1988; 72: 1944–1949
   PubMed Web of Science ®Google Scholar
• Kobari L., Weil D., Lemoine F. M., Dubois C., Thiam D., Baillou C., Guigon M., Gorin N. C., Najman A. Secretion of tumor necrosis factor alpha by fresh human acute non lymphoblastic leukemic cells: role in the disappearance of normal CFU‐GM progenitors. Exp. Hematol. 1990; 18: 1187–1192
   PubMed Web of Science ®Google Scholar
• Rogers S. Y., Bradbury D., Kozlowski R., Russell N. H. Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Exp. Hematol. 1994; 22: 593–598
   PubMed Web of Science ®Google Scholar
• Freedman M. H., Grunberger T., Correa P., Axelrad A. A., Dube I. D., Cohen A. Autocrine and paracrine growth control by granulocyte‐monocyte colony‐stimulating factor of acute lymphoblastic leukemia cells. Blood 1993; 81: 3068–3075
   PubMed Web of Science ®Google Scholar
• Miyauchi J., Keheller C. A., Yang Y., Wong G. G., Clark S. C., Minden M. D., Minkin S., McCulloch E. A. The effects of three recombinant growth factors, IL‐3, GM‐CSF and G‐CSF on the blast cells of acute myeloblastic leukemia maintained in short‐term suspension culture. Blood 1987; 70: 657–663
   PubMed Web of Science ®Google Scholar
• Eder M., Hemmati P., Kalina U., Ottmann O. G., Hoelzer D., Lyman S. D., Ganser A. Effects of Flt3 ligand and interleukin‐7 on in vitro growth of acute lymphoblastic leukemia cells. Exp. Hematol. 1996; 24: 371–377
   PubMed Web of Science ®Google Scholar
• Khoury E., André C., Pontvert‐Delucq S., Drenou B., Baillou C., Guigon M., Najman A., Lemoine F. M. TNFα down‐regulates c‐kit proto‐oncogene product expression in normal and acute myeloid leukemia CD34+ cells via p55 TNFα receptors. Blood 1994; 84: 2506–2514
   PubMed Web of Science ®Google Scholar
• Murohashi I., Endho K., Nishida S., Yoshida S., Jinnai I., Bessho M., Hirashima K. Differential effects of TGFβ1 on normal and leukemic human hematopoietic cell proliferation. Exp. Hematol. 1995; 23: 970–977
   PubMed Web of Science ®Google Scholar
• Lee G., Ellingsworth L. R., Gillis S., Wall R., Kincade P. W. β Transforming growth factors are potential regulators of B lymphopoiesis. J. Exp. Med. 1987; 166: 1290–1299
   PubMed Web of Science ®Google Scholar
• Urashima M., Ogata A., Chauhan D., Hatziyanni M., Vidriales M. B., Dedera D. A., Schlossman R. L., Anderson K. C. Transforming growth factor‐β1: Differential effects on multiple myeloma versus normal B‐cells. Blood 1996; 87: 1928–1938
   PubMed Web of Science ®Google Scholar
• Tohda S., Kurokawa H., Nara N. Diversity and similarity in signaling pathways of hematopoietic growth factors in human leukemia cell lines. Leukemia 1995; 9: 879–883
   PubMed Web of Science ®Google Scholar
• Chasty R., Lucas G. S., Owen‐Lynch P. J., Pierce A., Whetton A. D. Macrophage Inflammatory Protein‐la receptors are present on cells enriched for CD34 expression from patients with chronic myeloid leukemia. Blood 1995; 86: 4270–4277
   PubMed Web of Science ®Google Scholar